Serum Activins and Follistatin during the Treatment of Chronic Hepatitis C Genotypes 1 and 4 and Their Correlations with Viral Load and Liver Enzymes: A Preliminary Report

Aims. To measure the effect of pegylated interferon-α therapy on serum activin-A, activin-B, and follistatin and their correlation with viral load and liver fibrosis in chronic hepatitis C (CHC). Methods. This study was cross-sectional and sera were collected from 165 participants classified into 7...

Full description

Saved in:
Bibliographic Details
Main Authors: Bassem Refaat, Adel Galal El-Shemi, Ahmed Mohamed Ashshi, Adnan AlZanbagi
Format: Article
Language:English
Published: Wiley 2014-01-01
Series:Gastroenterology Research and Practice
Online Access:http://dx.doi.org/10.1155/2014/628683
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832564201058467840
author Bassem Refaat
Adel Galal El-Shemi
Ahmed Mohamed Ashshi
Adnan AlZanbagi
author_facet Bassem Refaat
Adel Galal El-Shemi
Ahmed Mohamed Ashshi
Adnan AlZanbagi
author_sort Bassem Refaat
collection DOAJ
description Aims. To measure the effect of pegylated interferon-α therapy on serum activin-A, activin-B, and follistatin and their correlation with viral load and liver fibrosis in chronic hepatitis C (CHC). Methods. This study was cross-sectional and sera were collected from 165 participants classified into 7 groups: 40 healthy negative control, 33 treatment naïve patients as positive control, 19 patients at week 4, 22 at week 12, and 19 at week 24 of treatment initiation and 21 responders and 11 nonresponders at the end of 48-week treatment protocol. Serum candidate proteins were measured using ELISA and liver fibrosis was assessed by AST platelet ratio index (APRI). Results. CHC significantly increased activins and decreased follistatin compared to negative control (P<0.05). Activin-A and follistatin levels returned to the levels of negative control group at weeks 4, 12, and 24 following treatment initiation and were significantly different from positive control (P<0.05). Both proteins were significantly different between responders and nonresponders. Activin-A correlated positively and significantly with the viral load and APRI. Conclusion. CHC modulates serum activin-A and follistatin and they appear to be influenced by pegylated interferon-α therapy. Further studies are needed to explore the role of activins in CHC.
format Article
id doaj-art-6b699b4a18334a62bf046f6ab78f6ab7
institution Kabale University
issn 1687-6121
1687-630X
language English
publishDate 2014-01-01
publisher Wiley
record_format Article
series Gastroenterology Research and Practice
spelling doaj-art-6b699b4a18334a62bf046f6ab78f6ab72025-02-03T01:11:36ZengWileyGastroenterology Research and Practice1687-61211687-630X2014-01-01201410.1155/2014/628683628683Serum Activins and Follistatin during the Treatment of Chronic Hepatitis C Genotypes 1 and 4 and Their Correlations with Viral Load and Liver Enzymes: A Preliminary ReportBassem Refaat0Adel Galal El-Shemi1Ahmed Mohamed Ashshi2Adnan AlZanbagi3Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, P.O. Box 7607, Al Abdeyah, Makkah, Saudi ArabiaLaboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, P.O. Box 7607, Al Abdeyah, Makkah, Saudi ArabiaLaboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, P.O. Box 7607, Al Abdeyah, Makkah, Saudi ArabiaGastroenterology Department, King Abdullah Medical City, Makkah 21955, Saudi ArabiaAims. To measure the effect of pegylated interferon-α therapy on serum activin-A, activin-B, and follistatin and their correlation with viral load and liver fibrosis in chronic hepatitis C (CHC). Methods. This study was cross-sectional and sera were collected from 165 participants classified into 7 groups: 40 healthy negative control, 33 treatment naïve patients as positive control, 19 patients at week 4, 22 at week 12, and 19 at week 24 of treatment initiation and 21 responders and 11 nonresponders at the end of 48-week treatment protocol. Serum candidate proteins were measured using ELISA and liver fibrosis was assessed by AST platelet ratio index (APRI). Results. CHC significantly increased activins and decreased follistatin compared to negative control (P<0.05). Activin-A and follistatin levels returned to the levels of negative control group at weeks 4, 12, and 24 following treatment initiation and were significantly different from positive control (P<0.05). Both proteins were significantly different between responders and nonresponders. Activin-A correlated positively and significantly with the viral load and APRI. Conclusion. CHC modulates serum activin-A and follistatin and they appear to be influenced by pegylated interferon-α therapy. Further studies are needed to explore the role of activins in CHC.http://dx.doi.org/10.1155/2014/628683
spellingShingle Bassem Refaat
Adel Galal El-Shemi
Ahmed Mohamed Ashshi
Adnan AlZanbagi
Serum Activins and Follistatin during the Treatment of Chronic Hepatitis C Genotypes 1 and 4 and Their Correlations with Viral Load and Liver Enzymes: A Preliminary Report
Gastroenterology Research and Practice
title Serum Activins and Follistatin during the Treatment of Chronic Hepatitis C Genotypes 1 and 4 and Their Correlations with Viral Load and Liver Enzymes: A Preliminary Report
title_full Serum Activins and Follistatin during the Treatment of Chronic Hepatitis C Genotypes 1 and 4 and Their Correlations with Viral Load and Liver Enzymes: A Preliminary Report
title_fullStr Serum Activins and Follistatin during the Treatment of Chronic Hepatitis C Genotypes 1 and 4 and Their Correlations with Viral Load and Liver Enzymes: A Preliminary Report
title_full_unstemmed Serum Activins and Follistatin during the Treatment of Chronic Hepatitis C Genotypes 1 and 4 and Their Correlations with Viral Load and Liver Enzymes: A Preliminary Report
title_short Serum Activins and Follistatin during the Treatment of Chronic Hepatitis C Genotypes 1 and 4 and Their Correlations with Viral Load and Liver Enzymes: A Preliminary Report
title_sort serum activins and follistatin during the treatment of chronic hepatitis c genotypes 1 and 4 and their correlations with viral load and liver enzymes a preliminary report
url http://dx.doi.org/10.1155/2014/628683
work_keys_str_mv AT bassemrefaat serumactivinsandfollistatinduringthetreatmentofchronichepatitiscgenotypes1and4andtheircorrelationswithviralloadandliverenzymesapreliminaryreport
AT adelgalalelshemi serumactivinsandfollistatinduringthetreatmentofchronichepatitiscgenotypes1and4andtheircorrelationswithviralloadandliverenzymesapreliminaryreport
AT ahmedmohamedashshi serumactivinsandfollistatinduringthetreatmentofchronichepatitiscgenotypes1and4andtheircorrelationswithviralloadandliverenzymesapreliminaryreport
AT adnanalzanbagi serumactivinsandfollistatinduringthetreatmentofchronichepatitiscgenotypes1and4andtheircorrelationswithviralloadandliverenzymesapreliminaryreport